Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 62-66

  Ioakimidis, Leukothea ^a   Patterson, Christopher ^a   Hunter, Zachary ^a   Soumerai, Jacob ^a   Manning, Robert ^a   Turnbull, Barry ^b   Sheehy, Patricia ^a   Treon, Steven ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BioBridges   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cyclophosphamide; Febrile neutropenia; Hematocrit; Immunoglobulin M; Prednisone; Waldenstr m; _{2< sub> microglobulin}

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEVER; HEMATOCRIT; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; BLOOD; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; IMMUNOGLOBULIN M; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649513155     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.016     Document Type: Article

References (18)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom Macroglobulinemia. Semin Oncol 2003; 30:110-5.
2. Harris, NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-49.
3. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27:120-6.
4. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated xadvanced follicular lymphoma. J Clin Oncol 2008; 26:4579-86.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32.
6. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Lo-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23:153-61.
7. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25:3344-9.
8. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002; 20:2327-33.
9. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15:1481-3.
10. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients with Waldenstrom Macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101:2593-8.
11. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6:380-3.
12. Treon SP, Branagan AR, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenström's macroglobulinemia. Blood 2008; Epub ahead of print.
13. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system (IPSS) for Waldenström's macroglobulinemia. Blood 2009; [In press].
14. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-8.
15. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41-8.
16. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol 2005; 16:132-8.
17. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452-7.
18. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom's Macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180. J Clin Oncol 2009. In press.